Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 55.6% YoY to 67.2x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -25.19 | — | — | — | 66.71 | — | — | — | — | 35.05 | — | — | 12.91 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.91 | 3.02 | 2.41 | 3.95 | 2.66 | 4.14 | 5.93 | 9.24 | 10.48 | 4.12 | 8.16 | 21.81 | 3.13 |
| — | -27.0% | -59.4% | -57.2% | -74.6% | +0.3% | -27.2% | -57.6% | +235.1% | -58.2% | -4.0% | -70.9% | -89.9% | |
| P/B Ratio | 9.46 | 8.64 | 6.74 | 8.04 | 7.14 | 10.27 | 11.83 | 11.28 | 8.63 | 4.86 | 5.92 | 7.91 | 5.62 |
| — | -15.9% | -43.0% | -28.7% | -17.3% | +111.1% | +99.9% | +42.6% | +53.6% | +65.5% | +265.5% | +262.3% | +266.1% | |
| P/FCF | — | 1594.40 | — | — | 33.56 | 1116.37 | — | — | — | — | — | — | 9.71 |
| — | +42.8% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 67.19 | — | — | 38.36 | 151.47 | — | — | — | 30.25 | — | — | 9.38 |
| — | -55.6% | — | — | — | +400.7% | — | — | — | — | — | — | — | |
| EV / EBIT | — | 75.97 | — | — | 31.47 | 93.16 | — | — | — | 26.26 | — | — | 9.84 |
| — | -18.5% | — | — | — | +254.8% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Ardelyx, Inc.'s operating margin was 4.2% in Q3 2025, up 19.0 pp QoQ and up 2.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -13.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 17.6% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.3% | 98.8% | 87.3% | 83.4% | 84.3% | 84.0% | 86.3% | 83.6% | 85.2% | 86.4% | 84.4% | 86.5% | 92.8% |
| — | +17.6% | +1.1% | -0.2% | -1.1% | -2.7% | +2.3% | -3.4% | -8.2% | +1.2% | -10.7% | +5.7% | -7.2% | |
| Operating Margin | -10.1% | 4.2% | -14.7% | -49.0% | 7.0% | 2.3% | -18.6% | -53.6% | -81.4% | 13.1% | -74.4% | -229.3% | 27.5% |
| — | +86.1% | +20.8% | +8.5% | +108.6% | -82.7% | +75.0% | +76.6% | -396.3% | +103.0% | +92.8% | +96.1% | +100.8% | |
| Net Margin | -15.1% | -0.9% | -19.5% | -55.5% | 4.0% | -0.8% | -22.5% | -57.6% | -83.8% | 11.8% | -76.7% | -235.5% | 24.2% |
| — | -6.7% | +13.1% | +3.7% | +104.8% | -107.0% | +70.7% | +75.5% | -446.2% | +102.6% | +92.8% | +96.1% | +100.7% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.2% | -0.7% | -13.4% | -25.8% | 2.8% | -0.5% | -11.0% | -16.7% | -16.1% | 4.2% | -13.8% | -23.9% | 12.9% |
| — | -24.5% | -21.1% | -54.5% | +117.4% | -112.6% | +19.8% | +30.2% | -224.3% | +111.0% | +70.0% | +37.4% | +129.3% | |
| ROA | -13.1% | -0.2% | -4.4% | -9.7% | 1.2% | -0.2% | -4.8% | -8.3% | -9.8% | 2.6% | -8.0% | -13.2% | 6.4% |
| — | +10.6% | +9.3% | -17.4% | +111.8% | -108.6% | +40.0% | +37.0% | -253.6% | +116.0% | +61.3% | +34.6% | +128.3% | |
| ROIC | -10.8% | 1.2% | -4.1% | -10.3% | 2.6% | 0.8% | -4.8% | -8.8% | -10.7% | 3.5% | -12.4% | -35.1% | 22.5% |
| — | +54.6% | +13.7% | -16.6% | +123.9% | -77.3% | +61.7% | +75.0% | -147.5% | +108.5% | +70.5% | +6.2% | +154.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Ardelyx, Inc.'s Debt/EBITDA ratio is 37.3x — elevated, raising questions about debt serviceability. The current ratio has improved 9.5% YoY to 4.41x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.25 | 1.35 | 1.48 | 1.06 | 0.89 | 0.66 | 0.71 | 0.70 | 0.34 | 0.18 | 0.28 | 0.32 | 0.37 |
| — | +103.9% | +107.5% | +53.1% | +163.8% | +266.4% | +151.8% | +119.7% | -9.5% | -67.6% | -60.4% | -47.3% | -32.7% | |
| Debt / EBITDA | — | 37.25 | — | — | 17.76 | 37.63 | — | — | — | 4.48 | — | — | 2.77 |
| — | -1.0% | — | — | — | +740.1% | — | — | — | — | — | — | — | |
| Current Ratio | 4.31 | 4.41 | 4.30 | 4.12 | 4.58 | 4.03 | 4.21 | 4.53 | 4.88 | 5.54 | 2.63 | 2.65 | 2.34 |
| — | +9.5% | +2.1% | -9.1% | -6.2% | -27.3% | +60.3% | +71.2% | +108.6% | +140.2% | +12.2% | +10.9% | -7.5% | |
| Quick Ratio | 4.11 | 4.11 | 4.03 | 3.81 | 4.31 | 3.87 | 3.99 | 4.36 | 4.64 | 5.35 | 2.50 | 2.57 | 2.29 |
| — | +6.3% | +0.9% | -12.6% | -7.1% | -27.6% | +59.4% | +69.5% | +102.4% | +134.1% | +11.3% | +11.1% | -9.4% | |
| Interest Coverage | — | 0.81 | -2.19 | -5.80 | 1.39 | 0.42 | -2.78 | -6.08 | -9.98 | 3.65 | -8.14 | -13.05 | 6.66 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArdelyx, Inc.'s current P/E is -25.2x. The average P/E over the last 1 quarters is 66.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ardelyx, Inc.'s current operating margin is -10.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ardelyx, Inc.'s business trajectory between earnings reports.